Volume Alert - GERN 2.94 Geron Corp $GERN Hit a high today of 3.33 Closing the day 10:30 at 2.94 +0.63 +27.27% With a day low of 2.91 and a total volume of 15,520,164.
GERN Recent Posts: http://investorshangout.com/Geron-Corporation-GERN-54220/
GERN Geron Corp Recent Headline News
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 35 mins ago
BDR: 1.64 (+0.34), GERN: 2.93 (+0.62), TUBE: 19.25 (+1.24), WYY: 1.48 (-0.10), YOD: 2.08 (-0.48), DGLY: 11.55 (-1.67), PBYI: 222.69 (-16.80), ENLK: 27.75 (-1.68), BHI: 58.78 (+0.03), SVM: 1.27 (+0.11)
Upgrade Alert for Geron (GERN)
Comtex SmarTrend(R) - 1 hr 51 mins ago
Geron (NASDAQ:GERN) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $2.31 on volume of 2.5 million shares, below average daily volume of 3.2 million. Geron share prices have moved between a 52-week high of $7.79 and a 52-week low of $0.91 and closed yesterday at 154% above that low price at $2.31 per share. Over the past week, the 200-day moving average (MA) has gone down 1.8% while the 50-day MA has declined 0.4%.
GERN: 2.93 (+0.62)
Geron up big premarket on J&J deal
Seeking Alpha - at Seeking Alpha - 1 hr 53 mins ago
GERN: 2.93 (+0.62)
Geron wins deal to develop blood disorder drug, could get $935M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:55PM CST
JNJ: 108.41 (-0.66), GERN: 2.93 (+0.62)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:37PM CST
TSE: 12.51 (-1.23), WB: 19.40 (-0.22), VJET: 12.20 (-0.04), ALDW: 17.36 (-0.23), FRSH: 9.14 (+0.33), GERN: 2.93 (+0.62), TUBE: 19.25 (+1.24), XON: 22.75 (-1.02), RTRX: 10.67 (-0.95), PBYI: 222.69 (-16.80)
Geron could get $935M in blood disorder drug deal
AP - Thu Nov 13, 4:06PM CST
NEW YORK (AP) — Geron Corp. said Thursday it could get more than $900 million from a deal to develop its blood disorder drug imetelstat with a unit of Johnson & Johnson.
JNJ: 108.41 (-0.66), GERN: 2.93 (+0.62)
Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson
at The Street - Thu Nov 13, 3:34PM CST
J&J is paying $35 million upfront to Geron for rights to the drug.
JNJ: 108.41 (-0.66), GERN: 2.93 (+0.62)
Geron Announces Global Strategic Collaboration with Janssen to Develop and Commercialize Imetelstat
Thomson Reuters ONE - Thu Nov 13, 3:15PM CST
Conference Call Scheduled for Friday Morning, November 14, 2014 at 8:30 AM EST
GERN: 2.93 (+0.62)
Geron's Risk/Reward Profile Improves As Near-Term Uncertainty Ends
Kanak Kanti De - at Seeking Alpha - Fri Nov 07, 12:06PM CST
GERN: 2.93 (+0.62)
Geron EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:28PM CST
GERN: 2.93 (+0.62)
After A Long Year, An Update on Geron's Myelofibrosis Drug is Disclosed
at The Street - Thu Nov 06, 8:57AM CST
he new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
GERN: 2.93 (+0.62), INCY: 69.17 (-2.04)
Geron Announces Presentations at American Society of Hematology Annual Meeting
Thomson Reuters ONE - Thu Nov 06, 8:15AM CST
MENLO PARK, Calif., November 6, 2014 - Geron Corporation (Nasdaq: GERN) today announced that five abstracts describing clinical and non-clinical data on imetelstat have been accepted for presentation at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Francisco, California from December 6-9, 2014. The abstracts were published today on the ASH website at www.hematology.org.
GERN: 2.93 (+0.62)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 111.44 (-1.28), GERN: 2.93 (+0.62), AMGN: 158.14 (-2.71), ABBV: 63.30 (-0.33), AEGR: 20.06 (-0.41), SNY: 46.47 (-0.06), REGN: 399.74 (-2.89)
Nasdaq stocks posting largest volume increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
UMPQ: 17.71 (+0.07), HBNK: 19.95 (unch), BRDR: 7.52 (+0.18), SAPE: 24.70 (+0.02), TAIT: 1.03 (+0.01), BASI: 2.28 (-0.13), GERN: 2.93 (+0.62), NYMX: 0.46 (-0.03), MTEX: 22.18 (+0.44), CKEC: 28.58 (+0.10), ALQA: 5.10 (+0.01)
Most active Nasdaq-traded stocks
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SAPE: 24.70 (+0.02), FB: 74.34 (+0.09), PLUG: 3.66 (-0.40), GERN: 2.93 (+0.62), ODP: 6.76 (+0.04), ARCP: 8.83 (+0.02), INTC: 33.73 (+0.05), GRPN: 7.75 (-0.02), MSFT: 49.76 (+0.15), AAPL: 113.55 (+0.73), CSCO: 25.91 (+0.23)
Hot Stock: Geron, Shares Drop 7.1% (GERN)
Comtex SmarTrend(R) - Tue Nov 04, 10:38AM CST
Geron (NASDAQ:GERN) is one of today's worst performing low-priced stocks, down 7.1% to $2.60 on 1.3x average daily volume. Thus far today, Geron has traded 2.7 million shares, vs. average volume of 2.0 million shares per day. The stock has underperformed the Dow (-7.1% to the Dow's -0.2%) and underperformed the S&P 500 (-7.1% to the S&P's -0.6%) during today's trading.
GERN: 2.93 (+0.62)
Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 04, 8:00AM CST
Geron's (GERN) third quarter results were totally overshadowed by the removal of the full clinical hold on the IND application for imetelstat.
CYTK: 4.23 (-0.01), MDVN: 106.35 (-0.86), BIIB: 302.76 (-15.22), GERN: 2.93 (+0.62)
Geron Corporation (GERN) Looks Strong: Stock Up 25.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:44AM CST
Geron Corporation (GERN) was a big mover last session, as the company saw its shares surge nearly 26% on the day
MDVN: 106.35 (-0.86), ONCY: 0.77 (-0.01), GERN: 2.93 (+0.62), ILMN: 179.94 (-5.06)
GERN Recent Posts: http://investorshangout.com/Geron-Corporation-GERN-54220/
GERN Geron Corp Recent Headline News
Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - 1 hr 35 mins ago
BDR: 1.64 (+0.34), GERN: 2.93 (+0.62), TUBE: 19.25 (+1.24), WYY: 1.48 (-0.10), YOD: 2.08 (-0.48), DGLY: 11.55 (-1.67), PBYI: 222.69 (-16.80), ENLK: 27.75 (-1.68), BHI: 58.78 (+0.03), SVM: 1.27 (+0.11)
Upgrade Alert for Geron (GERN)
Comtex SmarTrend(R) - 1 hr 51 mins ago
Geron (NASDAQ:GERN) was upgraded from Neutral to Overweight at Piper Jaffray today. The stock closed yesterday at $2.31 on volume of 2.5 million shares, below average daily volume of 3.2 million. Geron share prices have moved between a 52-week high of $7.79 and a 52-week low of $0.91 and closed yesterday at 154% above that low price at $2.31 per share. Over the past week, the 200-day moving average (MA) has gone down 1.8% while the 50-day MA has declined 0.4%.
GERN: 2.93 (+0.62)
Geron up big premarket on J&J deal
Seeking Alpha - at Seeking Alpha - 1 hr 53 mins ago
GERN: 2.93 (+0.62)
Geron wins deal to develop blood disorder drug, could get $935M
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:55PM CST
JNJ: 108.41 (-0.66), GERN: 2.93 (+0.62)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 4:37PM CST
TSE: 12.51 (-1.23), WB: 19.40 (-0.22), VJET: 12.20 (-0.04), ALDW: 17.36 (-0.23), FRSH: 9.14 (+0.33), GERN: 2.93 (+0.62), TUBE: 19.25 (+1.24), XON: 22.75 (-1.02), RTRX: 10.67 (-0.95), PBYI: 222.69 (-16.80)
Geron could get $935M in blood disorder drug deal
AP - Thu Nov 13, 4:06PM CST
NEW YORK (AP) — Geron Corp. said Thursday it could get more than $900 million from a deal to develop its blood disorder drug imetelstat with a unit of Johnson & Johnson.
JNJ: 108.41 (-0.66), GERN: 2.93 (+0.62)
Geron Licenses Experimental Myelofibrosis Drug to Johnson & Johnson
at The Street - Thu Nov 13, 3:34PM CST
J&J is paying $35 million upfront to Geron for rights to the drug.
JNJ: 108.41 (-0.66), GERN: 2.93 (+0.62)
Geron Announces Global Strategic Collaboration with Janssen to Develop and Commercialize Imetelstat
Thomson Reuters ONE - Thu Nov 13, 3:15PM CST
Conference Call Scheduled for Friday Morning, November 14, 2014 at 8:30 AM EST
GERN: 2.93 (+0.62)
Geron's Risk/Reward Profile Improves As Near-Term Uncertainty Ends
Kanak Kanti De - at Seeking Alpha - Fri Nov 07, 12:06PM CST
GERN: 2.93 (+0.62)
Geron EPS in-line, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 3:28PM CST
GERN: 2.93 (+0.62)
After A Long Year, An Update on Geron's Myelofibrosis Drug is Disclosed
at The Street - Thu Nov 06, 8:57AM CST
he new imetelstat data in myelofibrosis are contained in a just-released research abstract ahead of next month's American Society of Hematology ASH annual meeting.
GERN: 2.93 (+0.62), INCY: 69.17 (-2.04)
Geron Announces Presentations at American Society of Hematology Annual Meeting
Thomson Reuters ONE - Thu Nov 06, 8:15AM CST
MENLO PARK, Calif., November 6, 2014 - Geron Corporation (Nasdaq: GERN) today announced that five abstracts describing clinical and non-clinical data on imetelstat have been accepted for presentation at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Francisco, California from December 6-9, 2014. The abstracts were published today on the ASH website at www.hematology.org.
GERN: 2.93 (+0.62)
Biotech Stock Roundup: Regeneron's Eylea Stumbles, Geron Up on Lifting of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 05, 8:46AM CST
It was another earnings-focused week with several biotech companies yet to report third quarter results.
VRTX: 111.44 (-1.28), GERN: 2.93 (+0.62), AMGN: 158.14 (-2.71), ABBV: 63.30 (-0.33), AEGR: 20.06 (-0.41), SNY: 46.47 (-0.06), REGN: 399.74 (-2.89)
Nasdaq stocks posting largest volume increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
UMPQ: 17.71 (+0.07), HBNK: 19.95 (unch), BRDR: 7.52 (+0.18), SAPE: 24.70 (+0.02), TAIT: 1.03 (+0.01), BASI: 2.28 (-0.13), GERN: 2.93 (+0.62), NYMX: 0.46 (-0.03), MTEX: 22.18 (+0.44), CKEC: 28.58 (+0.10), ALQA: 5.10 (+0.01)
Most active Nasdaq-traded stocks
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
SAPE: 24.70 (+0.02), FB: 74.34 (+0.09), PLUG: 3.66 (-0.40), GERN: 2.93 (+0.62), ODP: 6.76 (+0.04), ARCP: 8.83 (+0.02), INTC: 33.73 (+0.05), GRPN: 7.75 (-0.02), MSFT: 49.76 (+0.15), AAPL: 113.55 (+0.73), CSCO: 25.91 (+0.23)
Hot Stock: Geron, Shares Drop 7.1% (GERN)
Comtex SmarTrend(R) - Tue Nov 04, 10:38AM CST
Geron (NASDAQ:GERN) is one of today's worst performing low-priced stocks, down 7.1% to $2.60 on 1.3x average daily volume. Thus far today, Geron has traded 2.7 million shares, vs. average volume of 2.0 million shares per day. The stock has underperformed the Dow (-7.1% to the Dow's -0.2%) and underperformed the S&P 500 (-7.1% to the S&P's -0.6%) during today's trading.
GERN: 2.93 (+0.62)
Geron Q3 Loss Wider, Shares Up on Removal of Clinical Hold - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 04, 8:00AM CST
Geron's (GERN) third quarter results were totally overshadowed by the removal of the full clinical hold on the IND application for imetelstat.
CYTK: 4.23 (-0.01), MDVN: 106.35 (-0.86), BIIB: 302.76 (-15.22), GERN: 2.93 (+0.62)
Geron Corporation (GERN) Looks Strong: Stock Up 25.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 7:44AM CST
Geron Corporation (GERN) was a big mover last session, as the company saw its shares surge nearly 26% on the day
MDVN: 106.35 (-0.86), ONCY: 0.77 (-0.01), GERN: 2.93 (+0.62), ILMN: 179.94 (-5.06)
